Skip to main content
Log in

Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We conducted a prospective analysis of somatostatin receptor scintigraphy using 111In radiolabeled pentetreotide, a somatostatin analog, in patients with breast cancer in the aim to visualize the primary tumor and axillary or parasternal metastatic extension because some malignant breast tumors express somatostatin receptors (SS-R) in 50%, approximately. An analysis of SS-R was performed by autoradiography.

Patients and methods.Thirteen patients with clinically suspected breast tumors (T1, T2), and at least one palpable axillary node (N1) were included. In vivo planar scintigrams were acquired 1, 4, and 24 h after subcutaneous, then after intravenous injections (24 h delay between injections). Improved 111In-pentetreotide uptake in invaded nodes after subcutaneous injection was hypothesized. Ex vivo scintigrams of surgical specimens were also acquired immediately after tumor resection and axillary dissection. Pathological examination and receptor autoradiography were performed on all surgical specimens.

Results.Among 11 pathologically proven malignant tumors (9 ductal and 2 lobular carcinomas), only four were scintigraphically visible although six expressed SS-R receptors in vitro. Among six pathologically proven malignant nodes, four expressed SS-R, including two visualized scintigraphically. Scintigrams acquired after subcutaneous injections were less sensitive than after intravenous injections. There were no false positive. False negatives occurred in cases with small tumors with low-density or heterogeneously distributed SS-R. There was no significant difference by histological type or prognostic factors.

Conclusion.Somatostatin receptor scintigraphy does not appear to be sensitive enough to evaluate axillary node extension of breast cancer or even to confirm the presence of tumoral tissue, and this whatever the administration route for 111In-pentetreotide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557, 1983

    Google Scholar 

  2. Kissin MW, Querci della Rovere G, Easton D, Westbuy G: Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73: 580–584, 1986

    PubMed  Google Scholar 

  3. Hoe AL, Iven D, Royle GT, Taylor I: Incidence of arm swelling following axillary clearance for breast cancer. Br J Surg 79: 261–262, 1992

    PubMed  Google Scholar 

  4. Fekete M, Wittiliff JL, Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormonereleasing hormone, somatostatin, epidemal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Clin Lab Anal 3: 137–147, 1989

    Google Scholar 

  5. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF-receptors. Int J Cancer 46: 416–420, 1990

    PubMed  Google Scholar 

  6. Reubi JC, Kvols LK, Waser B, et al.: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 5969–5977, 1990

    PubMed  Google Scholar 

  7. Reubi JC, Mazzucchelli L, Laissue J: Intestinal vessels express a high density of somatostatin receptors in human in-flammatory bowel disease. Gastroenterology 106: 951–959, 1994

    PubMed  Google Scholar 

  8. Viki-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic L: Expression of somatostain receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80: 2974–2979, 1995

    PubMed  Google Scholar 

  9. Reubi JC, Torhorst J: The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer 64: 1254–1260, 1989

    PubMed  Google Scholar 

  10. Bajc M, Ingvar C, Palmer J: Dynamic Indium-111-pentetreotide scintigraphy in breast cancer. J Nucl Med 37: 622–626, 1996

    PubMed  Google Scholar 

  11. Van Eijck CHJ, Krenning EP, Bootsma A, et al.: Somatostatin receptor scintigraphy in primary breast cancer. Lancet 343: 640–644, 1994

    PubMed  Google Scholar 

  12. Krenning EP, Kwekkeboom DJ, Bakker WH, et al.: Somatostatin receptor scintigraphy with [Indium-111-DTPA-DPhe-1] and [iodine-123-Tyr-3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–731, 1993

    PubMed  Google Scholar 

  13. Foekens JA, Portengen H, van Putten WLJ, et al.: Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermic growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989

    PubMed  Google Scholar 

  14. Vural G, Atasever MUT, Ozur I, Ozdemir A, Gokcora N: Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of having breast cancer: preliminary results. Eur J Nucl Med 24: 312–315, 1997

    PubMed  Google Scholar 

  15. Chiti A, Agresti R, Maffioli LS, et al.: Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. Eur J Nucl Med 24: 192–196, 1997

    PubMed  Google Scholar 

  16. Cimitan M, Volpe R, Candiani E, et al.: The use of thallium-201 in the preoperative detection of breast cancer: an adjuct to mammography and ultrasonography. Eur J Nucl Med 22: 1110–1117, 1995

    PubMed  Google Scholar 

  17. Lee VW, Sax EJ, McAneny DB, et al.: A complementary role for thallium-201 scintigraphy with manmmography in the diagnosis of breast cancer. J Nucl Med 34: 2095–2100, 1993

    PubMed  Google Scholar 

  18. Waxman AD, Ramanna L, Memsic LD, et al.: Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 34: 18–23, 1993

    PubMed  Google Scholar 

  19. Burak Z, Argon M, Memis A, et al.: Evaluation of palpable breast masses with 99mTc-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Comm 15: 604–612, 1994

    Google Scholar 

  20. Campeau RJ, Kronemer KA, Sutherland CM: Concordant uptake of Tc–99m sestamibi and T1-201 in unsuspected breast tumor. Clin Nucl Med 12: 936–937, 1992

    Google Scholar 

  21. Kao CH, Wang SJ, Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 21: 432–436, 1994

    PubMed  Google Scholar 

  22. Khalkhali I, Cutrone JA, Mena I, et al.: Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 196: 421–426, 1995

    PubMed  Google Scholar 

  23. Scopinaro F, Schillaci O, Scarpini M, et al.: Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 21: 984–987, 1994

    PubMed  Google Scholar 

  24. Dehdashti F, Mortimer JE, Siegel BA, et al.: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro assays. J Nucl Med 36: 1766–1774, 1995

    PubMed  Google Scholar 

  25. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187: 743–750, 1993

    PubMed  Google Scholar 

  26. Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S: Imaging of breast cancer with [18F]fluorodexyglucose and positron emission tomography. J Comput Assist Tomogr 13: 1097–1098, 1989

    PubMed  Google Scholar 

  27. Nieweg OE, Kim EE, Wong WH, et al.: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71: 3920–3925, 1993

    PubMed  Google Scholar 

  28. Tse NY, Hoh C, Hawkins RA, et al.: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216: 27–34, 1992

    PubMed  Google Scholar 

  29. Wahl RL, Cody RL, Hutchins GD, MudgeTT EE: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179: 765–770, 1991

    PubMed  Google Scholar 

  30. Minn H, Soini I: [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 15: 61–66, 1989

    PubMed  Google Scholar 

  31. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teräs M: Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67: 787–791, 1993

    PubMed  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albérini, J.L., Meunier, B., Denzler, B. et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 61, 21–32 (2000). https://doi.org/10.1023/A:1006447325077

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006447325077

Navigation